Montalban-Bravo et al. [5] demonstrated that individuals with NPM1-mutated MDS or MDS/MPN undergoing intensive chemotherapy exhibited elevated overall response rates (100%) and complete response rates (90%). This evidence concerns the gene NPM1 and myelodysplastic syndrome.